Glenmark Pharmaceuticals and BeiGene Announce Strategic Collaboration for Marketing and Distribution of Tislelizumab and Zanubrutinib in India

Glenmark Pharmaceuticals Limited, through its subsidiary Glenmark Specialty S.A., and BeiGene, a global oncology company, have entered into an exclusive marketing and distribution agreement. Under this partnership, Glenmark will register and commercialize BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib, in India. Alok Malik, President and Business Head - India Formulations at Glenmark Pharmaceuticals, expressed his excitement about the partnership, which underscores the company's commitment to advancing healthcare in India and providing access to novel therapies for cancer patients across the country.